Join
Live feed
·
PRReleasevia Quantisnow
Jyong Biotech Ltd. logo

Jyong Biotech Ltd. Signs Non‑Binding Letter of Intent with Leading South Korean Pharmaceutical Company to Evaluate In‑Licensing of Plant-Derived MCS Drugs

ByQuantisnow·Wall Street's wire, on your screen.
MENS· Jyong Biotech Ltd.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track MENS (Jyong Biotech Ltd.) and more on Quantisnow.